DEC = 3 sout

GROUP 1600





RESTRICTION ELECTION FACSIMILE TRANSMISSION

DATE: 12/6/00

FROM/ATTORNEY: Elias Lambins, Esg.

FIRM: Newzymes North America

PAGES, INCLUDING COVERSHEET: 3

PHONE NUMBER: 2/2-878-9674

TO EXAMINER:

P. Ponnaluri

ART UNIT:

1627

SERIAL NUMBER: 09/426,038

FAX/TELECOPIER NUMBER: (703) 308-4315

PLEASE NOTE: THIS FACSIMILE NUMBER IS TO BE USED ONLY

FOR RESPONSES TO RESTRICTIONS.

COMMENTS:

IF YOU HAVE NOT RECEIVED ALL THE PAGES OF THIS TRANSMISSION, PLEASE CONTACT THE ATTORNEY AT THE TELEPHONE NUMBER LISTED ABOVE.

IN COMPLIANCE WITH 1096 OG 30. THE FILING DATE ACCORDED EACH OFFICIAL FAX TRANSMISSION WILL BE DETERMINED BY THE FAX MACHINE DATE STAMP FOUND ON THE LAST PAGE OF THE TRANSMISSION, UNLESS THAT DATE IS A SATURDAY, SUNDAY, OR FEDERAL HOLIDAY WITHIN THE DISTRICT OF COLUMBIA, IN WHICH CASE THE OFFICIAL DATE OF RECEIPT WILL BE THE NEXT BUSINESS DAY.

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAIN(S) INFORMATION FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THIS INFORMATION IS FOR THE USE OF THE INDIVIDUAL OR FIRM NAMED ON THIS SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION, OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS INFORMATION IS STRICTLY PROHIBITED. THE DOCUMENTS SH ULD BE RETURNED TO THE PATENT AND TRADEMARK FFICE IMMEDIATELY. IF THIS FACSIMILE IS RECEIVED IN ERROR, PLEASE NOTIFY THE ATTORNEY LISTED HEREON IMMEDIATELY.





Attorney Docket No.: 5579.210-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Jesper Vind

Application No.: 09/426,038

Group Art Unit: 1627

Filed: October 25, 1999

Examiner: P. Ponnaluri

For: Methods Of Constructing And Screening A DNA Library Of Interest In Filamentous

Fungal Cells

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents Washington, DC 20231

Sir:

This paper is being filed in response to the Office Action mailed November 7, 2000 that made restriction and election of species requirements.

In response to these requirements, Applicants hereby elect with traverse Group I (i.e., claims 1-21). Applicants also elect the following species:

- a. replication initiating sequence: SEQ ID NO:1,
- b. polynucleotide sequences prepared by random mutagenesis,
- c. polynucleotide sequences that encode a polypeptide,
- d. polypeptides are enzymes,
- e. enzymes are hydrolases,
- f. hydrolases are proteases,
- g. control sequence is a promoter,
- h. promoter is TAKA-amylase promoter,
- i. selectable marker provides biocide resistance,
- j. no election necessary,
- k. pyrG,
- 1. replication initiating sequence of group a),

.

ביביח כבסיטרו

HEEL HITTHE GGGT'G '070

- m. SEQ ID NO:1,
- n. modification is performed by DNA shuffling, and
- o. fungal cell is Aspergillus.

Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Date: December 6, 2000

Elias J. Landiris, Reg. No. 33,728 Novo Nordisk of North America, Inc. 405 Lexington Avenue, Suite 6400 New York, NY 10174-6401

(212) 867-0123